

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | |
|---|--|---|
| (51) International Patent Classification ⁶ : A61K 31/38, 31/40, 31/44 | A1 | (11) International Publication Number: WO 95/33462 (43) International Publication Date: 14 December 1995 (14.12.95) |
| (21) International Application Number: PCT/US95/07038 (22) International Filing Date: 2 June 1995 (02.06.95) (30) Priority Data: 08/252,715 2 June 1994 (02.06.94) US (60) Parent Application or Grant (63) Related by Continuation US 08/252,715 (CON) Filed on 2 June 1994 (02.06.94) (71) Applicant (for all designated States except US): SMITHKLINE BEECHAM CORPORATION [US/US]; Corporate Intellectual Property, UW2220, 709 Swedeland Road, P.O. Box 1539, King of Prussia, PA 19406-0939 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): ADAMS, Jerry, Leroy [US/US]; 611 Forest Road, Wayne, PA 19087 (US). HALL, Ralph, Floyd [US/US]; 1311 Prospect Hill Road, Villanova, PA 19085 (US). LEE, Dennis [CA/US]; 205 Haverford Avenue, Swarthmore, PA 19081 (US). | (74) Agents: DINNER, Dara, L. et al.; SmithKline Beecham Corporation, Corporate Intellectual Property, UW2220, 709 Swedeland Road, P.O. Box 1539, King of Prussia, PA 19406-0939 (US). (81) Designated States: JP, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published With international search report. | |
| (54) Title: ANTI-INFLAMMATORY COMPOUNDS (57) Abstract This invention relates to the novel compounds and pharmaceutical compositions of formula (I) and formula (II). This invention also relates to a method of treating or reducing inflammation in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound or composition of formula (I) or formula (II). | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | |
|----|--------------------------|----|---------------------------------------|----|--------------------------|
| AT | Austria | GB | United Kingdom | MR | Mauritania |
| AU | Australia | GE | Georgia | MW | Malawi |
| BB | Barbados | GN | Guinea | NE | Niger |
| BE | Belgium | GR | Greece | NL | Netherlands |
| BF | Burkina Faso | HU | Hungary | NO | Norway |
| BG | Bulgaria | IE | Ireland | NZ | New Zealand |
| BJ | Benin | IT | Italy | PL | Poland |
| BR | Brazil | JP | Japan | PT | Portugal |
| BY | Belarus | KE | Kenya | RO | Romania |
| CA | Canada | KG | Kyrgyzstan | RU | Russian Federation |
| CF | Central African Republic | KP | Democratic People's Republic of Korea | SD | Sudan |
| CG | Congo | KR | Republic of Korea | SE | Sweden |
| CH | Switzerland | KZ | Kazakhstan | SI | Slovenia |
| CI | Côte d'Ivoire | LI | Liechtenstein | SK | Slovakia |
| CM | Cameroon | LK | Sri Lanka | SN | Senegal |
| CN | China | LU | Luxembourg | TD | Chad |
| CS | Czechoslovakia | LV | Latvia | TG | Togo |
| CZ | Czech Republic | MC | Monaco | TJ | Tajikistan |
| DE | Germany | MD | Republic of Moldova | TT | Trinidad and Tobago |
| DK | Denmark | MG | Madagascar | UA | Ukraine |
| ES | Spain | ML | Mali | US | United States of America |
| FI | Finland | MN | Mongolia | UZ | Uzbekistan |
| FR | France | | | VN | Viet Nam |
| GA | Gabon | | | | |

ANTI-INFLAMMATORY COMPOUNDS

FIELD OF THE INVENTION

5 This invention relates to pharmaceutical compositions and their use as anti-inflammatory agents in mammals.

BACKGROUND OF THE INVENTION

10 An early event in the response of most inflammatory cells to immunologic activation and other stimuli is the release of newly formed products (mediators) which alter the function and biochemistry of surrounding cells and tissues. The ensuing biological responses, as well as much of the pathogenesis which is attributed to inflammation and allergy, are thought to be dependent on the effects that these newly-formed mediators have on adjacent cells within the inflammatory region.

15 In the last 20 years, it has become apparent that lipid mediators are among the most potent and important products which are generated during inflammatory reactions. The synthesis of most lipid mediators is initiated by the specific cleavage of complex phospholipid molecules which contain arachidonate at their sn-2 position. Arachidonic acid is predominantly found in the sn-2 position of phospholipids after redistribution by
20 transacylases and its release by sn-2 acylhydroxylases from phospholipids represents the rate-limiting step in the formation of eicosanoids (leukotrienes, prostaglandins and thromboxanes) and other hydroxylated fatty acids. As arachidonic acid is released, it is then converted to oxygenated derivatives by at least two enzymatic systems (lipoxygenase and/or cyclooxygenase). Concomitant with arachidonate release, lysophospholipids are
25 formed. One of these lyso phospholipids, 1-alkyl-2-lyso-sn-glycero-3-phosphocholine, is then acetylated to form platelet-activating factor (PAF). Each of the cell types involved in the inflammatory response produce and secrete a unique subset of lipid mediators. The quantities and nature of the metabolites depend on which enzymes and precursor phospholipid pools are available to inflammatory cells.

30 Once lipid mediators such as PAF and eicosanoids are formed by the aforementioned pathways, they induce signs and symptoms observed in the pathogenesis of various inflammatory disorders. Indeed, the pathophysiological activity of arachidonic acid (and its metabolites) is well known to those skilled in the art. For example, these mediators have been implicated as having an important role in allergy, asthma,
35 anaphylaxis, adult respiratory distress syndrome, reperfusion injury, inflammatory bowel disease, rheumatoid arthritis, endotoxic shock, and cardiovascular disease. Aalmon et al., Br. Med. Bull (1978) 43:285-296; Piper et al., Ann. NY Acad. Sci. (1991) 629:112-119; Holtzman, Am. Rev. Respir. Dis. (1991) 143:188-203; Snyder, Am. J. Physiol. Cell Physiol. (1990) 259:C697-C708; Prescott et al., J. Biol. Chem. (1990) 265:17381-

-2-

17384.

Similar to arachidonate products, PAF is a potent proinflammatory mediator produced by a variety of cells. In vitro, PAF stimulates the movement and aggregation of neutrophils and the release therefrom of tissue-damaging enzymes and oxygen radicals.

5 PAF has also been implicated in activation of leukocytes, monocytes, and macrophages. These activities contribute to the actions of PAF as having (pathological) physiological activity in inflammatory and allergic responses. PAF has also been implicated in smooth muscle contraction, pain, edema, hypotensive action, increases in vascular permeability, cardiovascular disorders, asthma, lung edema, endotoxin shock, and adult respiratory
10 distress syndrome. PAF elicits these responses either directly through its own cellular receptor(s) or indirectly by inducing the synthesis of other mediators.

Accordingly, a method which antagonizes the production of free arachidonic acid, its metabolites or PAF will have clinical utility in the treatment of a variety of allergic, inflammatory and hypersecretory conditions such as asthma, arthritis, rhinitis, bronchitis
15 and urticaria, as well as reperfusion injury and other disease involving lipid mediators of inflammation. Many published patent applications or issued US patents exist which describe various compounds having utility as PAF or eicosanoid antagonists. Such patents include U.S. Pat. No. 4,788,205, 4,801,598, 4,981,860, 4,992,455, 4,983,592, 5,011,847, 5,019,581 and 5,002,941.

20 Phospholipase A₂'s (PLA₂ (EC 3.1.1.4)) are responsible for the liberation of arachidonic acid from the sn-2 position of phospholipid. They are thought to play an important role in the pathogenesis of inflammation and possibly in immunological dysfunction, both as a cell associated enzyme as well as an extracellular soluble enzyme. Low molecular weight, mammalian Type II 14 kDa PLA₂ has been well characterized and
25 is known to exist in both an extracellular form in inflammatory fluids (Kramer et al., J. Biol. Chem., 264:5768-5775 (1989) and in a cell associated form (Kanda et al., Biochemical and Biophysical Research Communications, 163:42-48 (1989) and has been found in a variety of cells and tissues or extracellularly when released in response to antigenic activators or pro-inflammatory mediators such as Interleukin (IL)-1, IL-6 or
30 tumor necrosis factor (TNF). Its presence in such inflammatory fluids, tissue exudates or serum has therefore implicated Type II-14 kDa-PLA₂'s role in inflammation (Vadas, et al., (1985) Life Sci. 36, 579-587; and Seilhamer, et al., (1989) J. Biol. Chem. 264, 5335-5338). Recently, the elevated serum levels of PLA₂ activity during an inflammatory insult has been attributed to cytokine induction of acute phase protein release from liver, of
35 which the 14 kDa-PLA₂ is suggested to be a part (Crowl, et al., (1991) J. Biol. Chem. 266, 2647-2651). In addition, soluble PLA₂ activity is markedly elevated in the serum and synovial fluid of patients with rheumatoid arthritis (Stefanski et al., J. Biochem.

100:1297-303 (1986). Furthermore, increasing serum PLA₂ levels have been shown to positively correlate with clinical severity (Bomalaski and Clark, Arthritis and Rheumat. 36:190-198 (1993)). Various inhibitors of PLA₂ have been described in publications and in US Patents. See for instance US Patents 4,959,357; 4,933,365; 5,208,223; 5,208,244; 5 Marshall et al., J. Rheumatology 18:1 (1991); Marshall et al., Phospholipase A₂, Ed. Pyu Wong, Plenum Press, NY (1990) pages 169-181; Wilkerson, et al., Eur. J. Med. Chem., 26:667, 1991 and Wilkerson, Antiinflammatory Phospholipase A₂ Inhibitors, Drugs of the Future, Vol. 15, No. 2 p 139-148(1990). Accordingly, as PLA₂ is important in the liberation of arachidonic acid from phospholipid and may also play a role in the generation of PAF via lysophospholipid formation, inhibition of such an enzyme would be useful for the treatment of disease states caused thereby.

There are many novel forms of phospholipase A₂'s which have recently been discovered. For the purposes herein, members of the sn-2 acylhydrolase family of PLA₂'s are divided into low and high molecular weight enzymes be it from mammalian, 15 or non-mammalian sources. Low molecular weight PLA₂'s will generally have a molecular weight in the range of 12,000 to 15,000. High molecular weight will be in the range of 30,000 or 56,000 kDa to 110,000 by SDS electrophoresis analysis.

A high molecular weight, cytosolic 85 kDa PLA₂ has been isolated and cloned from the human monocytic cell line, U937 (Clark et al., Proc. Natl. Acad. Sci., 87:7708- 20 7712, 1990). The cell-associated Type II-14 kDa-PLA₂ in cell lipid metabolism was thought to be the key rate limiting enzyme in lipid mediator formation, until the recent identification of this cell-associated but structurally distinct 85 kDa sn-2 acylhydrolase, (Clark, et al., supra); and Kramer, et al., (1991) J. Biol. Chem. 266, 5268-5272. Like the Type II-14 kDa enzyme, this enzyme is active at neutral pH and Ca²⁺-dependent, but 25 in contrast exhibits a preference for AA in the sn-2 position of phospholipid substrate and migrates from the cytosol to the membrane in a Ca²⁺-dependent manner and is regulated by phosphorylation (Kramer et al., J. Biol. Chem., 266:5268-5272 (1991). The 85 kDa-PLA₂ is also distinct from 14 kDa-PLA₂s and Ca²⁺-independent PLA₂ as demonstrated by different biochemical characteristics such as stability of the 85 kDa-PLA₂ to DTT, 30 instability to heat and the lack of inhibition by a phosphonate phospholipid TSA inhibitor of 14 kDa-PLA₂. In addition, 85 kDa-PLA₂ has been shown to possess a lysophospholipase A₁ activity which is not observed with the 14 kDa-PLA₂s. The 85 kDa enzyme is similar to the myocardial Ca²⁺-independent PLA₂ (Bomalaski and Clark, Arthritis and Rheumat. 36:190-198 (1993)) in that Ca²⁺ is not required for catalysis and DTNB 35 inhibition is observed. However, 85 kDa-PLA₂ is not inhibited by the suicide inactivator bromoenol lactone, suggesting that the enzyme is distinct from the myocardial enzyme as well. These characteristics make the 85 kDa-PLA₂ a candidate for participation in the

-4-

liberation of AA from phospholipid stores for subsequent metabolism to lipid mediators. Both the cytosolic 85 kDa PLA₂ and a cell associated Type II 14 kDa PLA₂ have been found in the human monocyte, neutrophil and platelet (Marshall and Roshak, *Biochem. Cell Biol.* 71:331-339 (1993)). As noted above most of the cellular lipid mediators found
5 elevated in a variety of inflammatory fluids are formed in response to non-pancreatic 14 kDa PLA₂ action.

Since arachidonate-containing phospholipids are the key precursors for a broad range of lipid mediators it would not be surprising that, inflammatory cells would treat these phospholipids differently than other fatty acid-containing phospholipids. In
10 particular, there are enzymes which control the amount of arachidonate in different phospholipid pools and these enzymes are tightly regulated to maintain arachidonate homeostasis. The movement of arachidonate into and from all phospholipids was originally thought to be exclusively by Coenzyme A-dependent acyl transferase activities. Holub *et al.*, *Adv. Lipid Res.*, 16:1-125 (1978); Lands *et al.*, In *The Enzymes of*
15 *Biological Membranes*, ed. Martonosi, A., pp. 3-85, Plenum Press, NY, 1976. However, it has now been demonstrated that an enzyme, Coenzyme A-independent transacylase (CoA-IT), is involved in the movement of 20 carbon higher unsaturated fatty acids, particularly arachidonate, into particular (1-alkyl- and 1-alkenyl) phospholipid pools. These are the phospholipid pools of arachidonate that are preferentially mobilized
20 during cell activation and utilized for eicosanoid and PAF biosynthesis, respectively.

CoA-IT has a specificity for certain phospholipids as donor and acceptor molecules. The fatty acid transferred is long chained and unsaturated, and almost exclusively arachidonate. Other fatty acids such as the 16:0, 18:1 or 18:2 are not moved into the sn-2 position of alkyl and 1-alkenyl phospholipid pools by CoA-IT. The
25 specificity of CoA-IT is in direct contrast to many other CoA-dependent acylation activities which acylate a wide variety of lysophospholipids with no selectivity for arachidonate.

Accordingly, as CoA-IT is involved in arachidonic acid and phospholipid metabolism, inhibition of such an enzyme would be useful for the treatment of inflammatory, allergic and hypersecretory conditions or disease states caused thereby.
30 Therefore, a method by which CoA-IT is inhibited will consequently and preferentially decrease the arachidonate content of 1-alkyl- and 1-alkenyl-linked phospholipids and will therefore decrease the production of pro-inflammatory mediators such as free arachidonic acid, prostaglandins, leukotriene and PAF during an inflammatory response.

35 SUMMARY OF THE INVENTION

This invention relates to the novel compounds and pharmaceutical compositions of Formula (I) which composition comprises a compound of Formula (I), or

-5-

pharmaceutically acceptable salt thereof and a pharmaceutically acceptable diluent or carrier.


This invention also relates to a method of treating or reducing inflammation in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound or composition of Formula (I).

This invention also relates to a method of treating disease or disorders mediated by lipid inflammatory mediators, free arachidonic acid, its metabolites and/or PAF by administering to a patient in need thereof, an effective amount of a compound of Formula (I).

This invention also relates to a method of treating disease or disorders mediated by phospholipase A₂ (PLA₂) and Coenzyme A independent transacylase (CoA-IT) by administering to a patient in need thereof, an effective amount of a compound or composition of Formula (I).

The present invention also relates to the novel compounds and compositions of Formula (II) comprising a compound of Formula (II), or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.

One aspect of the present invention are compounds of the structure represented by Formula (I):



wherein

R₁ is (CH₂)_nOH or (CH₂)_nCO₂H

n is 0 or an integer having a value of 1;

X is oxygen or sulfur;

W is -NH-, -N=CH-, or -S-;

R₂ is hydrogen, halogen, optionally substituted C₁₋₈ alkyl, or C₁₋₈ alkoxy;

m is an integer having a value of 1 or 2;

R₃ is S(O)₂R₇;

R₄ is hydrogen;

R₅ is hydrogen, halogen, CF₃, CH₃, (CH₂)_tC(O)₂R₈, or (CH₂)_tOH;

t is 0 or an integer having a value of 1 or 2;

R₆ is hydrogen or halogen;

R₇ is optionally substituted aryl, optionally substituted arylC₁₋₂ alkyl, or an optionally

-6-

substituted C₁₋₈ alkyl;
 R₈ is hydrogen or C₁₋₄ alkyl;
 or a pharmaceutically acceptable salt thereof.

5 DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed to a novel method of treating inflammatory disease in a mammal in need thereof by administering to said mammal an effective amount of a compound according to Formula (I) or (II). The compounds of Formula (I) and (II) may selectively inhibit the PLA₂ enzyme, the CoA-IT enzyme or both. Inhibition of either
 1 0 or both enzymes will result in the treatment of inflammatory occurrences in mammals. Inflammatory states in mammals may include, but are not limited to, allergic and asthmatic manifestations, dermatological diseases, inflammatory diseases, collagen diseases, reperfusion injury and stroke. Treatment of both acute and chronic diseases are possible. Preferred diseases for treatment are arthritis, asthma, allergic rhinitis, inflammatory bowel
 1 5 disease (IBD), psoriasis, reperfusion injury and stroke. For the purposes herein, the compounds of Formula (I) are preferential and selective inhibitors of the low molecular weight PLA₂ enzyme, and further all compounds of Formula (I) and (II) inhibit the PLA₂ enzyme.

2 0 For compounds of Formula (I), R₁ is suitably (CH₂)_nCO₂H and n is preferably 0. Suitably, R₂ is independently a substituent on the benzene ring from 0 to 2 times, and such substituent is suitably selected from hydrogen, halogen, an optionally substituted C₁₋₈ alkyl, or C₁₋₈ alkoxy group. Suitably when R₂ is halogen it is a chlorine or bromine. When R₂ is an optionally substituted C₁₋₈ alkyl, the alkyl is substituted one to
 2 5 three times with halogen, such as fluorine, preferably a trifluoromethyl group. The optionally substituted C₁₋₈ alkyl moiety is preferably a branched C₅ chain, such as 1,1-dimethyl propyl moiety or a C₈ branched chain such as 1,1,3,3-tetramethyl butyl moiety. Suitably m is an integer having a value of 0 or 1. Most preferably R₂ is hydrogen.

Suitably, R₃ is S(O)₂ R₇; and R₇ is an optionally substituted aryl, an optionally
 3 0 substituted arylC₁₋₂ alkyl, or an optionally substituted C₁₋₈ alkyl group. Suitably the aryl, aryl alkyl or alkyl moieties are substituted independently, one to three times, by halogen, trifluoromethyl, aryloxy, methoxy, CH₂OH, methyl, or C(O)₂H. Preferably, the substituents are halogen, or trifluoromethyl. The substituent halogen groups are preferably Cl, Br and fluorine. More preferably the substituents are in the 3,5- position or
 3 5 the 4-position of the aryl ring.

When R₇ is an aryl moiety it is preferably phenyl; when R₇ is an aryl alkyl moiety it is preferably benzyl; when R₇ is an alkyl moiety it is preferably a methyl or a C₈

-7-

unbranched chain. The methyl moiety, if substituted, is preferably substituted by one or more fluorines, such as in a trifluoromethyl group. More preferably R₇ is an optionally substituted phenyl. Suitably the aryl substituents are 3,5-bis-trifluoromethyl, 4-trifluoromethyl, 4-bromo, 4-chloro, or 4-fluoro.

5 Suitably R₅ is hydrogen, halogen, CF₃, CH₃, (CH₂)_tC(O)₂R₈, or (CH₂)_tOH; and t is 0 or an integer having a value of 1 or 2. Preferably t is 1 or 2. Preferably R₈ is a C₁₋₄ alkyl, preferably t-butyl. When R₅ is (CH₂)_tC(O)₂R₈, or (CH₂)_tOH it is preferably a CH₂C(O)₂R₈ group. Preferred R₅ groups are hydrogen, CF₃, or halogen, such as Cl, Br, F or I. More preferably R₅ is hydrogen, or CF₃.

10 Suitably R₆ is hydrogen or halogen, preferably hydrogen.

Specifically exemplified compounds of Formula (I) are:

3-[2-[3,5-Bis(trifluoromethyl)phenylsulfonamido]-4-trifluoromethylphenoxy]picolinic acid, and preferably its lithium salt

15 3-[2-[3,5-Bis(trifluoromethyl)phenylsulfonamido]-4-trifluoromethylphenoxy]-2-hydroxypyridine;

3-[2-[3,5-Bistrifluoromethyl]phenylsulfonamido]-4-trifluoromethylphenoxy]pyrrole-2-carboxylic acid;

20 3-[2-[3,5-Bistrifluoromethyl]phenylsulfonamido]-4-trifluoromethylphenoxythiophene-2-carboxylic acid.

Another aspect of the present invention are the novel compounds and pharmaceutical compositions of Formula (II) which composition comprises a compound of Formula (I), or pharmaceutically acceptable salt thereof and a pharmaceutically acceptable diluent or carrier.


This invention also relates to a method of treating or reducing inflammation in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound or composition of Formula (II).

30 This invention also relates to a method of treating disease or disorders mediated by free arachidonic acid, its metabolites and/or PAF by administering to a patient in need thereof, an effective amount of a compound of Formula (II).

This invention also relates to a method of treating disease or disorders mediated by phospholipase A₂ (PLA₂) and Coenzyme A independent transacylase (CoA-IT) by administering to a patient in need thereof, an effective amount of a compound or composition of Formula (II).

Compounds of Formula (II) are represented by a structure having the formula:

-8-



wherein

X is oxygen or sulfur;

R₂ is hydrogen, halogen, optionally substituted C₁₋₈ alkyl, or C₁₋₈ alkoxy;

5 m is an integer having a value of 1 or 2;

R₃ is S(O)₂R₇;

R₄ is hydrogen;

R₅ is hydrogen, halogen, CF₃, CH₃, (CH₂)_tC(O)₂R₈, or (CH₂)_tOH;

t is 0 or an integer having a value of 1 or 2;

10 R₆ is hydrogen or halogen;

R₇ is optionally substituted aryl, optionally substituted arylC₁₋₂ alkyl, or an optionally substituted C₁₋₈ alkyl;

R₈ is hydrogen or C₁₋₄ alkyl;

or a pharmaceutically acceptable salt thereof.

15

Preferred substituents for compounds of Formula (II) are the same as those noted herein for Formula (I). More preferred is where X is oxygen. More preferably is where m is 0 and R₂ is hydrogen, R₆ is hydrogen, R₅ is trifluoromethyl and R₇ is a substituted phenyl, preferably substituted twice by CF₃, more preferably as a 3,5-bis(trifluoromethyl) group.

20

A specifically exemplified compound of Formula (II) is:

2-[2-[3,5-Bis(trifluoromethyl)phenylsulfonamido]-4-trifluoromethylphenoxy]pyridine, and pharmaceutically acceptable salts thereof.

25

Suitable pharmaceutically acceptable salts are well known to those skilled in the art and include basic salts of inorganic and organic acids, such as hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methane sulphonic acid, ethane sulphonic acid, acetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid and mandelic acid. In addition, pharmaceutically acceptable salts of compounds of formula (I)

30

-9-

and (II) may also be formed with a pharmaceutically acceptable cation, for instance, if substituent R_1 comprises a carboxy group. Suitable pharmaceutically acceptable cations are well known to those skilled in the art and include alkaline, alkaline earth, ammonium and quaternary ammonium cations.

5

The following terms, as used herein, refer to:


- "halo" or "halogen" - all halogens, that is chloro, fluoro, bromo and iodo;
- " C_{1-8} alkyl" or "alkyl" - both straight and branched chain radicals of 1 to 8 carbon atoms, unless the chain length is otherwise limited, including, but not limited to, methyl, ethyl, *n*-propyl, *iso*-propyl, *n*-butyl, *sec*-butyl, *iso*-butyl, *tert*-butyl, and the like;
- "aryl" - phenyl and naphthyl;
- "arylalkyl" - is phenyl and naphthyl connected to a C_{1-4} alkyl as defined above, including, but not limited to, benzyl, and phenethyl.

1 5

The compounds of the present invention may contain one or more asymmetric carbon atoms and may exist in racemic and optically active forms. All of these compounds are included within the scope of the present invention.


2 0

Compounds of Formula (I) may be prepared by a process which comprises reacting a suitably protected compound of Formula (2) where R_1 is $(CH_2)_nC(O)_2H$, which are generally commercially available. While the schematic illustrated below describes compounds of Formula (I) compounds of Formula (II) may also be made in a similar manner,



2 5

with a compound of Formula (3) wherein R_9 is F, Cl, Br or I, and R_5 and R_6 are as in Formula (I):




3 0

-10-

in a suitable solvent such as dimethylformamide and in the presence of a suitable base such as potassium carbonate with or without added copper at a temperature of 25-175°C to provide a compound of Formula (4). In cases where compounds of Formula (2) are not commercially available, the desired compounds of formula (2) may be prepared by

- 5 following the various procedures disclosed in Drummond *et al.*, *J. Med. Chem.*, 1989, 32, 2116; Momose *et al.*, *Chem. Pharm. Bull.*, 1978, 26, 2224; and Huddleston *et al.*, *Synn. Comm.*, 1979, 9, 731 whose disclosures in their entirety are incorporated by reference herein.




10

(4)

Reduction of compound (4) with a suitable reducing agent such as iron in a solvent such as acetic acid/ethanol/water, or titanium trichloride in acetic acid water, or H_2 in the presence of a catalyst such as palladium on carbon in a solvent such as ethyl acetate or

15


methanol, provides a compound of Formula (5).



(5)

20

Reaction of compound (5) with a sulfonyl halide in a suitable solvent such as pyridine provides a compound of Formula (6) wherein R_4 is hydrogen.



(6)

-11-

Deprotection (if required) of a compound of Formula (6) and/or conversion to suitable salt forms provides a final compound of Formula (I). It is possible, if desired, to also deprotect the R₁ moiety in the compound of Formula (4) or Formula (5) and proceed with the reaction accordingly.

5

Compounds of Formula (II) are produced in an analogous manner to that above for compounds of Formula (I) and as exemplified by Example 2 in the Synthetic Chemistry section below.

10

Without further elaboration, it is believed that one skilled in the art can, using procedures analogous to those described herein, utilize the present invention to its fullest extent. The invention will now be described by reference to the following examples which are merely illustrative and are not to be construed as a limitation of the scope of the present invention.

15

SYNTHETIC CHEMISTRY

Temperatures are recorded in degrees centigrade unless otherwise noted.

Example 1

20

Preparation of 3-[2-[3,5-bis(trifluoromethyl)phenylsulfonamido]-4-trifluoromethylphenoxy]picolinic acid

a) Methyl 3-[2-nitro-4-trifluoromethylphenoxy]picolinate

To a stirred solution of 4-fluoro-3-nitrobenzotrifluoride (353 mg) and 129 mg methyl 3-hydroxypicolinate (prepared according to the procedure of Drummond *et al.*, *J. Med. Chem.*, 1989, 32, 2116) in DMF (4 mL) was added potassium carbonate (233 mg). The reaction was heated at 125°C for 16 h. The solution was cooled to rt, and H₂O (10 mL) was added. The mixture was extracted with ether (2X10 mL), and the combined extracts were dried (MgSO₄), filtered, and concentrated to afford an oil. Silica gel chromatography (ethyl acetate/hexanes) afforded 200 mg of the title compound. ¹H NMR(400 MHz, CDCl₃) δ 8.68 (d, J=4.1 Hz, 1H), 8.27 (s, 1H), 7.71 (d, J=8.7 Hz, 1H), 7.59 (m, 2H), 6.88 (d, J=8.8 Hz, 1 H), 3.87 (s, 3H).

30

b) Methyl 3-[2-amino-4-trifluoromethylphenoxy]picolinate

35

A mixture of methyl 3-[2-nitro-4-trifluoromethylphenoxy]picolinate (188 mg) and 10% Pd/C (20 mg) in ethyl acetate (10 mL) was shaken under H₂ pressure (55 psi) at rt for 2 days. The catalyst was filtered, and the solvent was removed under reduced

-12-

pressure. Silica gel chromatography (ethyl acetate/hexanes) afforded 164 mg of the title compound. ^1H NMR(400 MHz, CDCl_3) d 8.46 (d, $J=4.3$ Hz, 1H), 7.41 (dd, $J=8.2$, 4.4 Hz, 1H), 7.33 (d, $J=8.2$ Hz, 1H), 7.06 (s, 1H), 6.95 (d, $J=8.4$ Hz, 1H), 6.90 (d, $J=8.4$ Hz, 1H), 3.97 (s, 3H).

5

c) Methyl 3-[2-[3,5-bis(trifluoromethyl)phenylsulfonamido]-4-trifluoromethyl-phenoxy]picolinate

To a solution of methyl 3-[2-amino-4-trifluoromethylphenoxy]picolinate (164 mg) in pyridine (5 mL) was added 3,5-bis(trifluoromethyl)phenylsulfonyl chloride (182 mg) at 10 0°C. The solution was stirred for 2 days at rt. Saturated NaHCO_3 (10 mL) was added, and the reaction mixture was extracted with ether (2X15 mL). The combined extracts were dried (MgSO_4), and silica gel chromatography yielded 16 mg of the title compound. ^1H NMR(400 MHz, CD_3OD) d 8.49 (d, $J=4.6$ Hz, 1H), 8.31 (s, 2H), 8.24 (s, 1H), 7.88 (s, 1H), 7.58 (dd, $J=8.4$, 4.6 Hz, 1H), 7.41 (d, $J=8.7$ Hz, 1H), 7.24 (d, $J=8.3$ Hz, 15 1H), 6.74 (d, $J=8.7$ Hz, 1H), 3.73 (s, 3H).

d) 3-[2-[3,5-Bis(trifluoromethyl)phenylsulfonamido]-4-trifluoromethyl-phenoxy]picolinic acid (lithium salt)

To a solution of methyl 3-[2-[3,5-bis(trifluoromethyl)phenylsulfonamido]-4-trifluoromethylphenoxy]picolinate (16 mg) in MeOH (2 mL) was added 1N LiOH (0.324 mL) at rt. The reaction was warmed to 55°C for 2 h. The solution was cooled to rt and freeze dried. Reverse phase prep TLC (Whatman PLKC18F, 40% MeOH/ H_2O) yielded 12 mg of the title compound. MS(ES) m/e 573 $[\text{M}-\text{H}]^-$.

25

Example 2

Preparation of 2-[2-[3,5-bis(trifluoromethyl)phenylsulfonamido]-4-trifluoromethylphenoxy]pyridine

a) 2-[2-Nitro-4-trifluoromethylphenoxy]pyridine

30 Following the procedure of Example 1(a), except substituting 2-hydroxypyridine for methyl 3-hydroxypicolinate, the title compound was prepared (47%). ^1H NMR(400 MHz, CDCl_3) d 8.37 (s, 1H), 8.02 (d, $J=8.3$ Hz, 1H), 7.57 (d, $J=8.4$ Hz, 1H), 7.44-7.49 (m, 1H), 7.30 (d, $J=6.8$ Hz, 1H), 6.61 (d, $J=9.4$ Hz, 1H), 6.37 (t, $J=6.7$ Hz, 1H).

35

b) 2-[2-Amino-4-trifluoromethylphenoxy]pyridine

To a solution of 2-[2-nitro-4-trifluoromethylphenoxy]pyridine (200 mg) in 1:1 AcOH/ H_2O (3 mL) was added 20% TiCl_3 (3 mL). The reaction was stirred for 15 min,

-13-

and 10% NaOH was added until the solution became homogeneous. The mixture was extracted with ethyl acetate (2X25 mL), dried (MgSO₄), and the solvent was removed under reduced pressure to afford 160 mg of the title compound. ¹H NMR(400 MHz, CDCl₃) δ 7.46-7.51 (m, 1H), 7.28 (d, J=7.5 Hz, 1H), 7.20 (d, J=7.5 Hz, 1H), 7.12 (s, 2H), 6.70 (d, J=8.3 Hz, 1H), 6.34 (t, J=6.7 Hz, 1H).

c) 2-[2-[3,5-Bis(trifluoromethyl)phenylsulfonamido]-4-trifluoromethylphenoxy]pyridine

Following the procedure of Example 1(c), except substituting 2-[2-amino-4-trifluoromethylphenoxy]pyridine for 3-[2-amino-4-trifluoromethylphenoxy]picolinate, the title compound was prepared (39%). MS(ES) m/e 529 [M-H]⁻.

Example 3

Preparation of 3-[2-[3,5-bis(trifluoromethyl)phenylsulfonamido]-4-trifluoromethylphenoxy]-2-hydroxypyridine

a) 3-[2-Nitro-4-trifluoromethylphenoxy]-2-hydroxypyridine

Following the procedure of Example 1(a), except substituting 2,3-dihydroxypyridine for methyl 3-hydroxypicolinate and heating at 100°C instead of 125°C, the title compound was prepared (28%). ¹H NMR(400 MHz, CD₃OD) δ 8.29 (s, 1H), 7.84 (d, J=8.7 Hz, 1H), 7.56 (d, J=7.4 Hz, 1H), 7.41 (d, J=6.6 Hz, 1H), 7.16 (d, J=8.8 Hz, 1H), 6.46 (t, J=7.0 Hz, 1H).

b) 3-[2-Amino-4-trifluoromethylphenoxy]-2-hydroxypyridine

To 3-[2-nitro-4-trifluoromethylphenoxy]-2-hydroxypyridine (78 mg) in a mixture of AcOH (1 mL), EtOH (10 mL) and H₂O (9 mL) was added iron (300 mg). The mixture was heated at 90°C for 40 min. The solution was decanted, 10% NaOH (25 mL) was added, and the mixture was extracted with ethyl acetate (2 X 20 mL). The combined extracts were dried (MgSO₄), the solvent was removed under reduced pressure, and silica gel chromatography (MeOH/CH₂Cl₂) afforded 34 mg of the title compound. ¹H NMR(400 MHz, CD₃OD) δ 7.25 (d, J=5.4 Hz, 1H), 7.06-7.10 (m, 2H), 6.89 (s, 2H), 6.35(t, J=6.7 Hz, 1H).

c) 3-[2-[3,5-Bis(trifluoromethyl)phenylsulfonamido]-4-trifluoromethylphenoxy]-2-hydroxypyridine

Following the procedure of Example 1(c), except substituting 3-[2-amino-4-trifluoromethylphenoxy]-2-hydroxypyridine for 3-[2-amino-4-trifluoromethyl-

-14-

phenoxy]picolinate, the title compound was prepared (68%). MS(ES) m/e 545 [M-H]⁻.

Example 4

5 Preparation of 3-[2-[3,5-bis(trifluoromethyl)phenylsulfonamido]-4-trifluoromethylphenoxy]pyrrole-2-carboxylic acid

a) Ethyl 3-[-2-nitro-4-trifluoromethylphenoxy]pyrrole-2-carboxylate

Following the procedure of Example 1(a), except substituting ethyl 3-
10 hydroxypyrrole-2-carboxylate (prepared according to the procedure of *Momose et al.*,
Chem. Pharm. Bull., 1978, 26, 2224) for methyl 3-hydroxypicolinate and heating at 90°C
instead of 125°C, the title compound was prepared (93%). ¹H NMR(400 MHz, CDCl₃) δ
9.22 (br s, 1H), 8.19 (s, 1H), 7.66 (d, J=7.1 Hz, 1H), 7.12 (d, J=7.5 Hz, 1H), 6.96 (br
s, 1H), 6.18 (br s, 1H), 4.16 (q, J=5.8 Hz, 2H), 1.02 (t, J=5.8 Hz, 3H).

15

b) Ethyl 3-[-2-amino-4-trifluoromethylphenoxy]pyrrole-2-carboxylate

Following the procedure of Example 2(b), except substituting ethyl 3-[-2-nitro-4-
trifluoromethylphenoxy]pyrrole-2-carboxylate for 2-[2-nitro-4-
trifluoromethylphenoxy]pyridine, the title compound was prepared (63%). ¹H NMR(400
20 MHz, CDCl₃) δ 8.88 (br s, 1H), 7.02 (s, 1H), 6.84-6.91 (m, 3H), 6.03 (br s, 1H), 4.23
(q, J=5.8 Hz, 2H), 1.18 (t, J=5.8 Hz, 3H).

c) Ethyl 3-[2-[3,5-bis(trifluoromethyl)phenylsulfonamido]-4-trifluoromethylphenoxy]pyrrole-2-carboxylate

Following the procedure of Example 1(c), except substituting ethyl 3-[-2-amino-4-
trifluoromethylphenoxy]pyrrole-2-carboxylate for 3-[2-amino-4-trifluoromethyl-
phenoxy]picolinate, the title compound was prepared (63%). ¹H NMR(400 MHz, CDCl₃)
δ 8.89 (br s, 1H), 8.27 (s, 2H), 8.20 (br s, 1H), 8.00 (s, 1H), 7.93 (s, 1H), 7.32 (d,
J=7.1 Hz, 3H), 6.94 (d, J=7.9 Hz, 1H), 6.81 (br s, 1H), 5.86 (br s, 1H), 4.21 (q,
30 J=5.8 Hz, 2H), 1.18 (t, J=5.8 Hz, 3H).

d) 3-[2-[3,5-bis(trifluoromethyl)phenylsulfonamido]-4-trifluoromethylphenoxy]pyrrole-2-carboxylic acid

To a solution of ethyl 3-[2-[3,5-bis(trifluoromethyl)phenylsulfonamido]-4-
35 trifluoromethylphenoxy]pyrrole-2-carboxylate (25 mg) in MeOH (1 mL) was added 1N
LiOH (0.40 mL) at rt. The reaction was warmed to 50°C for 8 h. The solution was

-15-

cooled to rt, acidified with 3N HCl (10 mL), and extracted with CH₂Cl₂ (2X15 mL). Removal of solvent under reduced pressure and silica gel chromatography (AcOH/MeOH/CH₂Cl₂) afforded 11 mg of the title compound. MS(ES) m/e 561 [M-H]⁻.

5

Example 5

Preparation of 3-[2-[3,5-bis(trifluoromethyl)phenylsulfonamido]-4-trifluoromethylphenoxy]thiophene-2-carboxylic acid

Following the procedure of Example 4(a)-4(d), except substituting methyl 3-hydroxythiophene-2-carboxylate (prepared according to the procedure of *Huddleston et al., Synn. Comm.*, 1979, 9, 731) for ethyl 3-hydroxypyrrrole-2-carboxylate. MS(ES) m/e 578 [M-H]⁻.

METHODS OF TREATMENT

The compounds of Formula (I) and (II), or pharmaceutically acceptable salts thereof, can be used in the manufacture of a medicament for the prophylactic or therapeutic treatment of an inflammatory disease state in a mammal, preferably a human.

Inhibition of PLA₂ and/or CoA-IT and the simultaneous reduction of PAF, free arachidonic acid and eicosanoid release from inflammatory cells according to this invention is of therapeutic benefit in a broad range of diseases or disorders. The invention herein is therefore useful to treat such disease states both in humans and in other mammals.

Inhibition of CoA-IT and 14 kDa PLA₂ by the compounds of Formula (I) and/or Formula (II) is an effective means for simultaneously reducing PAF, free arachidonic acid and eicosanoids produced in inflammatory cells. The therapeutic utility of blocking lipid mediator generation has been recognized for many years. For example, inhibitors of cyclooxygenase, such as aspirin, indomethacin, acetaminophen and ibuprofen, have demonstrated broad therapeutic utilities. CoA-IT inhibitors inhibit cyclooxygenase products. Another class of inhibitors which are used in a broad range of inflammatory disorders are the corticosteroids. Corticosteroids act in a variety of ways, e.g. to induce inflammatory cells to produce proteins which inhibit free arachidonic acid release or to down regulate PLA₂ mRNA formation. Both 14 kDa PLA₂ inhibitors and CoA-IT inhibitors block the release of free arachidonic acid. Inhibitors of 5-lipoxygenase block the production of leukotrienes and leukotriene antagonists prevent the bioactions of leukotrienes. Recent studies indicate that both will have broad therapeutic utilities. Both 14 kDa PLA₂ inhibitors and CoA-IT inhibitors block the production of leukotrienes. Inhibitors of phospholipase A₂ block the release of free arachidonic acid and the formation

-16-

of lyso PAF (the immediate precursor of PAF). PLA₂ inhibitors are recognized to have broad therapeutic utilities. It does not, however, follow that the disease states noted above must in fact be caused by altered CoA-IT or PLA₂ activity. Thus, the disease state itself may not be directly mediated by CoA-IT or PLA₂ activity. It only follows that CoA-IT or PLA₂ activity is required for the continued expression of symptoms of the disease state and that CoA-IT or PLA₂ inhibitors will be beneficial against the symptoms of these disease states.

Recognition that 14 kDa PLA₂ and/ or CoA-IT inhibitors reduce PAF production has a number of therapeutic implications. PAF itself has been implicated as being involved in a number of medical conditions. Thus in circulatory shock, which is characterized by systemic hypotension, pulmonary hypertension and increased lung vascular permeability, the symptoms can be mimicked by infusion of PAF. This coupled with evidence showing that circulating PAF levels are increased by endotoxin infusion indicate that PAF is a prime mediator in certain forms of shock.

Intravenous infusion of PAF at doses of 20-200 pmol kg⁻¹ min⁻¹ into rats has been reported to result in the formation of extensive haemorrhagic erosions in the gastric mucosa. Thus PAF is the most potent gastric ulcerogen yet described whose endogenous release may underlie or contribute to certain forms of gastric ulceration. Psoriasis is an inflammatory and proliferative disease characterized by skin lesions. PAF is pro-inflammatory and has been isolated from lesioned scale of psoriatic patients indicating PAF has a role in the disease of psoriasis. And finally, increasing evidence supports a potential patho-physiological role for PAF in cardiovascular disease. Thus recent studies in angina patients show PAF is released during atrial pacing. Intracoronary injection of PAF in pigs induces a prolonged decrease in coronary flow and, in guinea pig hearts, it induces regional shunting and ischemia. In addition PAF has been shown to initiate thrombus formation in a mesenteric artery preparation, both when administered exogenously and when released endogenously. More recently PAF has been shown to play a role in brain ischemia induced in animal models of stroke. Thus the compounds of the invention, by virtue of their ability to antagonize either CoA-IT and/or PLA₂, thus block the production of PAF, free arachidonic acid and its metabolites, are likely to be of value in the treatment of any of the above conditions.

The action of a PLA₂ inhibitor can be distinguished from the activity of a CoA-IT inhibitor based on their specific actions on their respective enzymes and by their different effects in cellular assays. For example only CoA-IT inhibitors have the ability to interfere with the mobilization of radiolabelled arachidonic acid to move from the alkyl-PC pool to the alkenyl PE pool. Selective inhibitors of 14 kDa PLA₂ are without an effect in this assay (assay E). Alternatively, CoA-IT inhibitors will inhibit both LTC₄ and PGE₂

-17-

release from activated monocytes while selective PLA₂ inhibitors inhibit LTC₄ release but spare prostanoid formation or production (assay F).

5 Disease states which could benefit from the inhibition of lipid mediator production include, but are not limited to, adult respiratory distress syndrome, asthma, arthritis, reperfusion injury, endotoxic shock, inflammatory bowel disease, allergic rhinitis and various inflammatory skin disorders. Each of these disorders is mediated in some part by lipid mediators of inflammation. Compounds which inhibit CoA-IT, by virtue of their ability to block the generation of lipid mediators of inflammation, are of value in the treatment of any of these conditions. Similarly compounds which inhibit PLA₂, by virtue of their ability to block the generation of lipid mediators of inflammation stemming from activation and/or release of this enzyme are of value in the treatment of these conditions. In particular, an inhibitor of CoA-IT, for instance would offer an advantage over the classical NSAIDs which affect only prostanoid production (and not PAF biosynthesis) thereby inhibiting both the acute and cell-mediated "chronic" inflammatory processes. Further an advantage of the PLA₂ inhibitor would be their affect on human monocyte leukotrienes and PAF formation, while immunosuppressive prostanoids, such as PGE₂, are spared. Likewise, selective inhibition of COX-2, by compounds herein, is useful for the treatment of diseases mediated thereby, such as arthritis, and IBD, for relief of pain, and inflammation, without the gastric and renal side effects associated with COX-1 inhibition.

20 Treatment of disease states caused by these lipid inflammatory mediators i.e., arachidonate, eicosanoids and PAF, include certain cardiovascular disorders such as but not limited to, myocardial infarction, stroke, circulatory shock, or hypotension, ischemia, reperfusion injury; inflammatory diseases such as, but not limited to, arthritis, inflammatory bowel disease, Crohn's disease, or ulcerative colitis; respiratory diseases such as but not limited to, asthma, or adult respiratory distress syndrome; anaphylaxis, shock, such as but not limited to endotoxic shock; topical diseases, such as but not limited to actinic keratosis, psoriasis, or contact dermatitis; or pyresis.

30 In order to use a compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof in therapy, it will normally be formulated into a pharmaceutical composition in accordance with standard pharmaceutical practice. This invention, therefore, also relates to a pharmaceutical composition comprising an effective, non-toxic amount of a compound of formula (I) and a pharmaceutically acceptable carrier or diluent.

35 Compounds of formula (I) or (II), pharmaceutically acceptable salts thereof and pharmaceutical compositions incorporating such may conveniently be administered by any of the routes conventionally used for drug administration, for instance, orally, topically, parenterally or by inhalation. The compounds of formula (I) and (II) may be administered

-18-

in conventional dosage forms prepared by combining a compound of formula (I) or (II) with standard pharmaceutical carriers according to conventional procedures. Such pharmaceutically acceptable carriers or diluents and methods of making are well known to those of skill in the art, and reference can be found in such texts as Remington's
5 Pharmaceutical Sciences, 18th Ed., Alfonso R. Genarao, Ed., 1990, Mack Publishing Co. and the Handbook of Pharmaceutical Excipients, APhA Publications, 1986.

The compounds of formula (I) and (II) may also be administered in conventional dosages in combination with known second therapeutically active compounds, such as steroids or NSAID's for instance. These procedures may involve mixing, granulating and
1 0 compressing or dissolving the ingredients as appropriate to the desired preparation. It will be appreciated that the form and character of the pharmaceutically acceptable carrier or diluent is dictated by the amount of active ingredient with which it is to be combined, the route of administration and other well-known variables. The carrier(s) must be
1 5 "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

The pharmaceutical carrier employed may be, for example, either a solid or liquid. Exemplary of solid carriers are lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and the like. Exemplary of liquid carriers are syrup, peanut oil, olive oil, water and the like. Similarly, the carrier or diluent may
2 0 include time delay material well known to the art, such as glyceryl mono-stearate or glyceryl distearate alone or with a wax.

A wide variety of pharmaceutical forms can be employed. Thus, if a solid carrier is used, the preparation can be tableted, placed in a hard gelatin capsule in powder or pellet form or in the form of a troche or lozenge. The amount of solid carrier will vary widely
2 5 but preferably will be from about 25mg. to about 1g. When a liquid carrier is used, the preparation will be in the form of a syrup, emulsion, soft gelatin capsule, sterile injectable liquid such as an ampule or nonaqueous liquid suspension.

Compounds of formula (I) may be administered topically, that is by non-systemic administration. This includes the application of a compound of formula (I) or (II)
3 0 externally to the epidermis or the buccal cavity and the instillation of such a compound into the ear, eye and nose, such that the compound does not significantly enter the blood stream. In contrast, systemic administration refers to oral, intravenous, intraperitoneal and intramuscular administration.

Formulations suitable for topical administration include liquid or semi-liquid
3 5 preparations suitable for penetration through the skin to the site of inflammation such as liniments, lotions, creams, ointments or pastes, and drops suitable for administration to the eye, ear or nose. The active ingredient may comprise, for topical administration, from

-19-

0.001% to 10% w/w, for instance from 1% to 2% by weight of the formulation. It may however comprise as much as 10% w/w but preferably will comprise less than 5% w/w, more preferably from 0.1% to 1% w/w of the formulation.

5 Lotions according to the present invention include those suitable for application to the skin or eye. An eye lotion may comprise a sterile aqueous solution optionally containing a bactericide and may be prepared by methods similar to those for the preparation of drops. Lotions or liniments for application to the skin may also include an agent to hasten drying and to cool the skin, such as an alcohol or acetone, and/or a moisturizer such as glycerol or an oil such as castor oil or arachis oil.

10 Creams, ointments or pastes according to the present invention are semi-solid formulations of the active ingredient for external application. They may be made by mixing the active ingredient in finely-divided or powdered form, alone or in solution or suspension in an aqueous or non-aqueous fluid, with the aid of suitable machinery, with a greasy or non-greasy base. The base may comprise hydrocarbons such as hard, soft or
15 liquid paraffin, glycerol, beeswax, a metallic soap; a mucilage; an oil of natural origin such as almond, corn, arachis, castor or olive oil; wool fat or its derivatives or a fatty acid such as steric or oleic acid together with an alcohol such as propylene glycol or a macrogel. The formulation may incorporate any suitable surface active agent such as an anionic, cationic or non-ionic surfactant such as a sorbitan ester or a polyoxyethylene
20 derivative thereof. Suspending agents such as natural gums, cellulose derivatives or inorganic materials such as siliceous silicas, and other ingredients such as lanolin, may also be included.

 Drops according to the present invention may comprise sterile aqueous or oily solutions or suspensions and may be prepared by dissolving the active ingredient in a
25 suitable aqueous solution of a bactericidal and/or fungicidal agent and/or any other suitable preservative, and preferably including a surface active agent. The resulting solution may then be clarified by filtration, transferred to a suitable container which is then sealed and sterilized by autoclaving or maintaining at 98-100 °C. for half an hour. Alternatively, the solution may be sterilized by filtration and transferred to the container by an aseptic
30 technique. Examples of bactericidal and fungicidal agents suitable for inclusion in the drops are phenylmercuric nitrate or acetate (0.002%), benzalkonium chloride (0.01%) and chlorhexidine acetate (0.01%). Suitable solvents for the preparation of an oily solution include glycerol, diluted alcohol and propylene glycol.

 Each dosage unit for oral administration contains preferably from 1 to 250 mg (and
35 for parenteral administration contains preferably from 0.1 to 25 mg) of a compound of the formula (I) or (II) or a pharmaceutically acceptable salt thereof calculated as the free base.

 The pharmaceutically acceptable compounds of the invention will normally be

-20-

administered to a subject in a daily dosage regimen. For an adult patient this may be, for example, an oral dose of between 1 mg and 500 mg, preferably between 1 mg and 250 mg, or an intravenous, subcutaneous, or intramuscular dose of between 0.1 mg and 100 mg, preferably between 0.1 mg and 25 mg, of the compound of the Formula (I)/(II) or a
5 pharmaceutically acceptable salt thereof calculated as the free base, the compound being administered from 1 to 4 times per day.

The choice of form for administration, as well as effective dosages, will vary depending, inter alia, on the condition being treated. The choice of mode of administration and dosage is within the skill of the art.

1 0

BIOLOGICAL METHODS:

To determine activity of the compounds of Formula (I) or (II) various cellular assays can be used to determine in vitro activity. Additionally, various classical in vivo acute inflammatory models which have some aspect of their etiology to elevated
1 5 eicosanoid levels can be employed, such as the paw edema model, mouse zymosan peritonitis, reverse Arthus pleurisy or various skin inflammation assays which are described in Lewis et al., Experimental Models of Inflammation, in the Handbook of Inflammation, Vol. 5, Bonta Ed., Elsevier Science Publishers, NY (1985) whose disclosure is herein incorporated by reference. The TPA induced ear edema model
2 0 (mouse) as well as the carrageenan paw edema model in the rat are described herein as well. These classical models of inflammation will reflect the drug's ability to alter an inflammatory response but cannot address the specificity of drug action. These models have been traditionally designed as non steriod antiinflammatory drug sensitive pharmacological screens and it is important to utilize models which can differentiate PLA2
2 5 and CoA-IT inhibitors from NSAIDS.

Cell-free and Cellular Assessment of Inhibitors

Described herein are several in vitro assays both for CoA-IT and PLA₂ enzyme activities. The first employs purified recombinant enzyme or a broken cell assay, assay (a or b,
3 0 respectively) described below. Alternatively, evaluation of inhibitors can occur in intact cells such as described in the assay, assay (c and d) below. CoA-IT activity can exclusively be measured, and differentiated from PLA₂ inhibition, in intact cells by following the movement of a pulse of [³H] arachidonate as it moves into the 1-alkyl and 1-alkenyl phospholipids in inflammatory cells (assay e). It should be noted for the purposes
3 5 herein that assays c, d, & f can both be used for PLA₂ and CoA-IT inhibition determination.

Inflammatory Responses *in vivo*

The ability of compounds that inhibit CoA-IT and/or PLA₂ to affect *in vivo* inflammatory responses may be assessed. Inflammatory responses are induced in the mouse ear by the topical application of a pro-inflammatory agent, such as 12-O-tetradecanoylphorbol 13-acetate (assay g). This produces an edematous response, as measured by increases in ear thickness, as well as increased inflammatory cellular infiltrate, as measured by increases in myeloperoxidase activity (as described in the methods). To further validate the mechanism of action inflammation induced by the direct administration of arachidonic acid can be used. In this case compounds altering arachidonic acid mobilization or liberation should be with our effect.

In Vitro Assays

Assay (a): Phospholipase A₂ assay:

Phospholipase A₂ activity of rh Type II- 14 kDa PLA₂ or PLA₂ semi-purified from human synovial joint fluid was measured by the acylhydrolysis of high specific activity (NEN)[³H]-AA-*E. coli* (0.5 mCi/5nmol PL Pi) as previously described in Marshall et al., J. Rheumatology, 18:1, pp59-65 (1991). High specific activity [³H]AA-*E. coli* had up to 95% of the label incorporated into phospholipid which was localized almost exclusively in the sn-2 position, as demonstrated by purified 14kDa PLA₂ or low molecular weight PLA₂ acylhydrolysis and separation of products by thin layer chromatography (TLC) (data not shown). [Predominately used herein was rh Type II 14 kDa PLA₂, or alternatively bovine pancreatic PLA₂ was also be used]. The reaction mixture (50 or 100 ml total volume) contained 25 mM HEPES, pH 7.4, 150 mM NaCl, 5 mM CaCl₂ and [³H]-AA-*E. coli* (low specific activity; 5-8 nmol PL Pi per assay). Assays were incubated for a time predetermined to be on the linear portion of a time versus hydrolysis plot. Experiments were conducted with final % hydrolysis values ranging from 2% (400-1000 dpm) to 10% (2000-5000 dpm) acylhydrolysis after blank correction. Reactions were terminated by the addition of 1.0 mL tetrahydrofuran (THF). The whole sample was placed over aminopropyl solid phase silica columns and eluted with THF:acetic acid (49:1) exclusively separating free fatty acids with greater than 95% recovery. Radiolabel in this eluate was quantitated by liquid scintillation counting. Results were expressed as % of fatty acid hydrolyzed ([sample dpms - non-specific (blank) dpms/total dpms] x 100) or specific activity which was calculated from hydrolysis values found in the linear portion of time versus % hydrolysis plots (pmol free fatty acid hydrolyzed/mg/min). Non-specific activity was always less than 1% of the total counts added.

-22-

Protein determination

All protein concentrations were determined by Bradford protein analysis kits (Biorad, Richmond, CA).

5 Results:

Representative compounds of Formula (I), Examples 1 to 5 all demonstrated positive PLA₂ inhibition in the method noted above. While these compounds generally tested positive at 50 μ m levels, several were also tested for positive inhibitory activity at higher levels.

10

Assay (b) : CoA-IT Activity

The following is a method to measure CoA-IT activity and the effects of compounds on CoA-IT activity. The assay is based upon mixing cellular material containing CoA-IT activity with a stable lyso phospholipid such as 1-alkyl-2-acyl-GPC and measuring the production of phospholipid product such as 1-alkyl-2-acyl-GPC occurring in the absence of added CoA or CoA-fatty acids.

15

Cell Preparation

Any inflammatory cell that contains high levels of CoA-IT activity can be used, such as neutrophils, macrophages or cell lines such as U937 cells. U937 cells were obtained from American Type Culture Collection and grown in RPMI-1640 media (Gibco, Grand Island, New York) supplemented with 10% fetal bovine serum (Hyclone, Logan, UT) at 37°C, 5%CO₂. Cells were grown without differentiation (basal state) by any agent, such as dimethyl sulfoxide. As used herein, "inflammatory cells" include, but are not limited to neutrophils, macrophages, monocytes, lymphocytes, eosinophils, basophils, and mast cells.

20

25

Microsomal preparation

Microsomes are prepared using standard techniques. In this case, cells are washed with a buffer of 250 mM sucrose, 10 mM Tris, 1 mM EGTA, 1 mM MgCl₂, pH 7.4 and ruptured by N₂ cavitation (750 psi, 10 minutes). The ruptured cells are centrifuged 1000 X g, 5 minutes. The resulting supernatant is centrifuged at 20,000 X g, ~20 minutes. Microsomes are prepared from this supernatant by centrifugation at 100,000 x g, 60 minutes. The resulting pellet is washed once with assay buffer (150 mM NaCl, 10 mM Na₂KPO₄, 1 mM EGTA, pH 7.4), recentrifuged and the pellet resuspended in assay buffer (4-20 mg protein/ml) and is stored at -80°C until assayed.

30

35

CoA-IT activity

CoA-IT activity is measured in 1.5 ml centrifuge tubes in a total volume of 100 μ l. Microsomes are diluted in assay buffer to the desired protein concentration (6-20 μ g/tube). The reaction is initiated by addition of [3H] 1-alkyl-2-lyso-sn-glycero-3-phosphocholine (GPC) (~0.1 μ Ci/tube) and 1 μ M final cold 1-alkyl-2-lyso-GPC in assay buffer with 0.25 mg/ml fatty acid-poor bovine serumalbumin (BSA) (Calbiochem, La Jolla, CA). [3H]1-alkyl-2-lyso-GPC, approximately 50 Ci/mmol, is from NEN-Dupont (Boston, Massachusetts) and cold 1-alkyl-2-lyso-GPC is from Biomol (Plymouth Meeting, Pennsylvania). Microsomes are pretreated with desired agents for the desired time (10 minutes) before the addition of [3H]1-alkyl-2-lyso-GPC. The reaction is run for the desired time (10 minutes) at 37°C. The reaction is stopped and the lipids extracted by addition of 100 μ l of chloroform:methanol (1:2, v/v) followed by 100 μ l of chloroform and 100 μ l of 1 M KCl. The samples are vortexed and centrifuged at high speed in a microfuge for 2-3 minutes. An aliquot of the chloroform-extracted materials are separated, usually by TLC in chloroform/methanol/acetic acid/water (50:25:8:4, v/v), visualized by radioscanning (Bioscan) and the product, [3H] 1-alkyl-2-acyl-GPC, is scraped and quantified by liquid scintillation spectroscopy. With this TLC system, the synthetic standards of 1-alkyl-2-lyso-GPC and 1-alkyl-2-acyl-GPC are well separated, with R_f values of approximately 0.25 and 0.65, respectively. Other methods can be used to separate substrate from product, including but not limited to column chromatography, affinity chromatography and post reaction derivitization.

Protein concentration are assessed using the protein assay reagents from Bio-Rad (Richmond, California).

Results

A variety of compounds have been tested in this assay to determine its selectivity and inability to detect trivial, non-selective inhibitors. Inhibitors of 5-lipoxygenase (5-LO) and cyclooxygenase (CO), such as indomethacin, naproxen, 6-(4'-Fluorophenyl)-5-(4-pyridyl)-2,3-dihydroimidzo-[2,1-b]thiazole and 6-(4'-Fluorophenyl)-5-(4-pyridyl)2,3-dihydroimidzo-[2,1-b]thiazole-dioxide had no effect on CoA-IT activity at concentrations up to 100 μ M. The anti-oxidant BHT also has no effect at concentrations up to 100 μ M. Compounds which complex with phospholipids and inhibit PLA₂ activity, such as quinacrine and aristolochic acid have no effect on CoA-IT activity at concentrations up to 500 μ M. Doxepine, a compound reported to inhibit PAF release did not inhibit CoA-IT at concentrations up to 100 μ M. Sodium diclofenac, reported to decrease leukotriene production by altering arachidonic acid metabolism, had no effect on CoA-IT activity at concentrations up to 500 μ M. These results show that the assay for CoA-IT activity is

-24-

sensitive and selective.

Assay (c): Arachidonic Acid Release Assay

5 Preparation of human neutrophils

Human neutrophils are obtained in the laboratory using three different methods. One method uses leukophoresis packs from normal humans and neutrophils are isolated using the histopaque-1077 technique. The blood is centrifuged at 300 x g for 10 minutes. The cell pellets are resuspended in PBS composed of 137 mM NaCl, 8.8 mM Na₂HPO₄,
1 0 1.5 mM KH₂PO₄, 2.7 mM KCl (Dulbecco's Gibco Laboratories, Long Island, New York) and layered over histopaque-1077 (Sigma, St. Louis, Missouri). The pellets are collected after centrifugation (300 x g for 30 minutes) and washed once in PBS. The cell pellets are exposed briefly to deionized water to lyse any erythrocytes. The remaining cells are collected by centrifugation, suspended in PBS, counted and identified after
1 5 cytopinning and staining. The final leukocyte preparation will be of greater than 95% purity and viability.

The second method isolates human neutrophils from fresh heparinized normal blood using the Histopaque-1077 technique. The blood is layered over Histopaque-1077 (Sigma, St. Louis Missouri) and centrifuged at 400 x g for 30 minutes. The cell pellets are
2 0 resuspended in 35 ml of PBS and 12 ml of 6% Dextran, followed by Dextran sedimentation at room temperature for 45 minutes. The upper layer is collected and further centrifuged for 10 minutes at 1000 rpm. The cell pellets are exposed briefly to deionized water to lyse erythrocytes. The remaining cells are collected by centrifugation, suspended in PBS, counted and identified after cytopinning and staining. The final
2 5 leukocyte preparation will be of greater than 95% purity and viability.

The third method isolates human neutrophils from freshly drawn heparinized normal blood using the Percoll technique. The blood is first treated with 6% Dextran at room temperature for a 1 hour sedmination. The upper layers of plasma are collected and centrifuged at 400 x g for 10 minutes. The cell pellets are resuspended in Percoll 1.070
3 0 g/ml supplemented with 5% fetal bovine serum and layered on discontinuous gradients (1.080, 1.085, 1.090, 1.095 g/ml) followed by centrifugation at 400 x g for 45 minutes. The neutrophils are collected from interfaces of 1.080 and 1.085 and the 1.085 and 1.090 Percoll densities, followed by a centrifugation at 400 x g for 45 minutes. The neutrophils are suspended in PBS, counted and identified after cytopinning and staining. The final
3 5 leukocyte preparation will be of greater than 95% purity and viability.

There should be no difference noted in the response of the neutrophils nor in the effects of test compounds in neutrophils isolated by the three different techniques.

-25-

Treatment of human neutrophils

Neutrophils are suspended in PBS with 1 mM Ca^{2+} and 1.1 mM Mg^{2+} at concentrations of 5 to 20 x 10⁶ cells per ml. Cells are added to test tubes and treated with the desired compounds for 5 to 10 minutes, then challenged with calcium ionophore A23187, 2 μM , or vehicle control, PBS containing 0.25-1 mg/ml BSA. After 5 to 20 minutes, the reactions are terminated by addition of an equal volume of chloroform:methanol (1:2, v/v) to the samples. [²Hg]Arachidonic acid (50, 100 or 200 ng) is added as an internal standard and the lipids were extracted by addition of equal volumes of chloroform and distilled water. The samples are vortexed and centrifuged at high speed and the chloroform layer removed to a clean tube.

Assay for free arachidonic acid

The chloroform extract for each sample is evaporated to dryness and the material resuspended in hexane. The hexane is passed through a Silica solid phase column (500 mg), washed 2x with hexane and a fatty acid enriched fraction eluted with hexane:ethyl ether (1:1, v/v). Solvents are removed from the samples under a stream of nitrogen then the samples are converted to pentafluorobenzyl esters using pentafluorobenzyl bromide and diisopropylethylamine in acetonitrile. Solvents are removed and samples are suspended in hexane. GC/MS analysis is performed on a suitable instrument, such as a Finnigan MAT TSQ 700 GC/MS/MS/DS (San Jose, California) operated as a single stage quadrupole system or a Hewlett-Packard 5890 with a 5989A M5 system.

The peaks corresponding to arachidonic acid and [²Hg]Arachidonic acid are identified and the areas of those peaks compared and the released arachidonic acid calculated as ng of arachidonic acid for each sample.

Protein concentrations are assessed using the protein assay reagents from Bio-Rad (Richmond, CA).

30

Assay (d): Assay for Production of Platelet-Activating Factor (PAF)Preparation of human neutrophils:

Blood is obtained from normal humans and neutrophils are isolated as described for the arachidonic acid release assay, above. The final leukocyte preparation should be of greater than 95% purity and viability.

Treatment of human neutrophils

-26-

Neutrophils are suspended in PBS at concentrations of 5 to 20×10^6 cells per ml. Cells are added to test tubes and treated with the desired compounds for 5 to 10 minutes, then challenged with calcium ionophore A23187, $2 \mu\text{M}$ and 20 - $30 \mu\text{Ci}$ of $[^3\text{H}]$ acetic acid (NEN-Dupont, Boston, Massachusetts), or the vehicle of PBS with 0.25 - 1 mg/ml . After 5 to 20 minutes, the reactions are terminated by addition of an equal volume of chloroform:methanol ($1:2$, v/v) to the samples and the lipids are extracted by addition of equal volumes of chloroform and distilled water. The samples are vortexed and centrifuged at high speed and the chloroform layer removed to a clean tube.

10 Assay for PAF

The chloroform from each tube is evaporated to dryness and the material suspended in a small volume of chloroform or chloroform:methanol (25 - $100 \mu\text{l}$) and the total material spotted on a Silica TLC plate. The plates are developed in chloroform:methanol/ acetic acid/water ($50:25:8:4$, v/v) visualized by radioscanning (Bioscan) and the product, $[^3\text{H}]$ PAF, is scraped and quantified by liquid scintillation spectroscopy. With this TLC system, the R_f value for a synthetic standard of PAF is approximately 0.33 .

20 Assay (e): Methods for the evaluation of CoA-IT inhibitors on mobilization of labeled arachidonic acid in intact cells

Measurement of the effect of CoA-IT inhibitors on the transfer of $[^3\text{H}]$ arachidonate into 1-ether phospholipids in non-stimulated inflammatory cells can be accomplished by general application of the following specific method. Human neutrophils are isolated and resuspended ($5 \times 10^7/\text{ml}$) in Hanks Balanced Salt Solution (HBSS; Gibco). $[5,6,8,9,11,12,14,15\text{-}^3\text{H}]$ -Arachidonic acid (100 Ci/mmol ; New England Nuclear) complexed to $200 \mu\text{l}$ HBSS containing 0.25 mg/ml HSA is added to the cell suspension ($1 \mu\text{Ci/ml}$). The cells are incubated with gentle shaking at 37°C for 5 min. The reaction is terminated by the addition of 40 ml ice-cold HBSS containing HSA (0.25 mg/ml). The cells are then removed from the supernatant fluid by centrifugation (225 g , 8 min). Unincorporated $[^3\text{H}]$ -arachidonic acid is completely removed by two more washes of HBSS containing 0.25 mg/ml HSA. The neutrophils are resuspended in fresh buffer, exposed to various concentrations of a CoA-IT inhibitor or its vehicle and incubated without stimulation for 2 hrs. At that time, the tubes containing the cells and buffer are extracted (Bligh & Dyer [Can. J. Biochem. Physiol. (1959) 37, 911-917]) and the phospholipid classes are separated and collected by normal phase HPLC, using a Ultrasphere Silica column ($4.6 \text{ mm} \times 250 \text{ mm}$; Rainin) eluted with hexane/2-propanol/ethanol/phosphate buffer ($\text{pH } 7.4$)/acetic acid ($490:367:100:30:0.6 \text{ v/v}$) for 5

-27-

min at a flow rate of 1 ml/min. The amount of phosphate buffer in the eluting solvent is increased to 5 % over 10 min and this solvent composition is maintained until all the phospholipid classes is eluted from the column (30-40 min) (Chilton, F. H. [Methods Enzymol. (1990)187, 157-166]). The phospholipids are converted into diradylglycerols by addition of phospholipase C, 20 units-40 units of *Bacillus cereus* phospholipase C (Sigma Type XIII) in 100 mM Tris HCl buffer (pH 7.4) for 2.5-6 hr, then converted into 1,2-diradyl-3-acetyl-glycerols by incubation with acetic anhydride and pyridine (Chilton, F. H. [Methods Enzymol. (1990)187, 157-166]). The phospholipid subclasses are separated by TLC in benzene/hexane/ethyl ether (50:45:4, v/v), located by image analysis (Bioscan) and the amount of radioactivity in each class is determined by zonal scraping and liquid scintillation counting.

The following is the method for assessing the ability of a compound to alter arachidonate content of cellular phospholipids, which can be generalized for any desired cell. Specifically, mouse bone marrow-derived mast cells are removed from culture and provided with exogenous [^3H]arachidonic acid for 30 minutes. The labeled arachidonic acid which had not been incorporated into the cells is then removed by washing the cells 2 times with an albumin-containing buffer. At that point, the cells are treated with various concentrations of CoA-IT inhibitors and then placed back in culture for 24-48 hours. The phospholipids are extracted by the method of Bligh and Dyer [Can. J. Biochem. Physiol. (1959) 37, 911-917] and phospholipids separated by normal phase HPLC by the method of Chilton [Methods Enzymol. (1990)187, 157-166]. The radioactive and mole quantities of arachidonate in complex lipids are determined. At this point, cellular lipid extracts are treated with KOH (0.5 M) to remove fatty acids from complex lipids (phospholipids) and the quantities of arachidonate in these extracts can then be determined by various methods, including gas chromatography and mass spectrometry (Chilton [Methods Enzymol. (1990)187, 157-166]).

Assay (f): Measurement of stimulated eicosanoid release by human monocytes.

Human Monocyte Isolation. Leukocyte-rich leukopaks obtained from Biological Specialties (Lansdale, PA) are collected from male volunteers who are not taking anti-inflammatory drugs. Leukopaks are centrifuged (90 x g for 15 min) twice to remove the platelet-rich plasma. The cell pellet is washed by centrifugation and are resuspended in HBSS without Ca^{2+} or Mg^{2+} . Histopaque 1077 is layered under the cell suspension and

-28-

centrifuged at 400 x g for 30 min to obtain the buffy coat. The interfacial buffy coat, containing monocytes and lymphocytes, is removed and saved. The buffy coat is washed twice with HBSS without Ca^{2+} or Mg^{2+} by centrifugation. The cell pellet (4-6 x 10⁸ cells/30mls) is resuspended in iso-osmotic media (RPMI-1640, 10% heat inactivated fetal bovine serum (FBS), 0.2 mM L-glutamine, 2.5 mM HEPES) and layered over an equal volume of 46% Percoll mixture (10 X PBS/ Percoll; 9.25 / 0.75) and 54% iso-osmotic media and centrifuged for 30 min at 1000 x g (Marshall and Roshak, Biochem. Cell Biol. 71: 331-339, 1993). The monocyte population located at the interface of the Percoll gradient is removed and washed twice in HBSS without Ca^{2+} or Mg^{2+} . This resulted in a greater than 85-90 % pure monocyte population as assessed by differential staining.

Measurement of Stimuli-Induced Eicosanoid Release. Monocytes (5 x 10⁶/ml) are incubated as a suspension in serum-free RPMI-1640 medium containing the vehicle DMSO (< 1%) or drug for 30 min at 27°C after which vehicle or stimuli is added for the indicated time. The stimulating agent is solubilized in DMSO and appropriate vehicle controls are included in all experiments. The amount of stimuli is chosen from the linear portion of a concentration versus product curve usually representing 60-80% maximal stimulation over the indicated incubation time at 37°C (A23187, 1 μM , (15 min). The reaction is terminated by reduction of pH through addition of citric acid and centrifugation (10 min, 400 x g, 4°C). Cell viability is monitored before and after experiments using trypan blue exclusion. The cell-free media is decanted and stored at -70° C until analyzed. Prostaglandin E₂ and LTC₄ are directly measured in cell-free media using enzyme immunoassay (EIA) kits purchased from Caymen Chemical Co. (Ann Arbor, MI). Sample or standard dilutions are made with appropriate media and analyzed in triplicate. Results are obtained by extrapolation from a standard curve prepared in the media and expressed as pg or ng/ml of sample.

In vivo assays

3 0 Assays (g and h) : Assay (Method) for TPA (assay g) or Arachidonic acid (assay h)-induced Inflammation

Animals:

3 5 Male Balb/c inbred mice are obtained from Charle River Breeding Laboratories (Kingston, NY). Within a single experiment mice (22-25g) are age-matched. These *in vivo* experiments typically involve the use of 5-6 animals/group.

(g) TPA-induced Mouse Ear Inflammation:

-29-

Assay of Ear Edema

TPA (12-O-tetradecanoylphorbol 13-acetate) (Sigma Chemical Company) in acetone (4 mg/20ml) is applied to the inner and outer surfaces of the left ear of BALB/c male mice. The thickness of both ears is then measured with a dial micrometer (Mitutoyo, Japan) at both 2 and 4 hours after treatment, and the data expressed as the change in thickness (10^{-3} cm) between treated and untreated ears. The application of acetone does not cause an edematous response; therefore, the difference in ear thickness represents the response to the TPA. After measuring the edema, the inflamed left ears are removed and stored at -70°C until they are assayed for MPO (myeloperoxidase) activity where appropriate.

Assay of Myeloperoxidase (MPO) in Inflamed Ear Tissue:

On the day of the assay, partially thawed ear tissues are minced and then homogenized (10% w/v) with a Tissumizer homogenizer (Tekmar Co.) in 50 mM phosphate buffer (pH 6) containing 0.5% HTAB. The tissue homogenates are taken through three cycles of freeze-thaw, followed by brief sonication (10 sec). The method of Bradley et al. is used with modifications as described. The appearance of a colored product from the MPO-dependent reaction of o-dianisidine (0.167 mg/ml; Sigma) and hydrogen peroxide (0.0005%; Sigma) is measured spectrophotometrically at 460 nm. Supernatant MPO activity is quantified kinetically (change in absorbance measured over 3 min, sampled at 15-sec intervals) using a Beckman DU-7 spectrophotometer and a Kinetics Analysis package (Beckman Instruments, Inc.). One unit of MPO activity is defined as that degrading one micromole of peroxide per minute at 25°C .

Statistics:

Statistical analysis is done using Student's "t" test. The ED_{50} are values which cause a 50% inhibition of the inflammatory response and are calculated by regression analysis of the dose response data.

(h) Arachidonic acid induced ear inflammation assay

Arachidonic acid is dissolved in acetone (1mg/ear) to the left ear of BALB/c male mice. The thickness of both ears is measured with a constant pressure thickness gauge 1 hour after treatment and the data expressed as the change in thickness between treated and untreated ears. Test compounds or vehicle are given at the time of AA application. The inflammatory cell infiltration is measured by MPO activity as described above in the TPA ear edema assay. After the edema measurements are made, the inflamed ears are removed and assayed for MPO activity.

-30-

The anti-inflammatory effect of various standard inhibitors topically administered in the AA and TPA induced mouse ear edema model were measured for dexamethasone, scalaradial and Wyeth's compound WY 50,295 at doses of 0.2, 0.1 and 0.3 respectively. The TPA % change in edema was -50 ($p < 0.001$), -46 ($p < 0.01$) and -18 (ns) respectively; for AA the change was -10 (ns), -11 (ns) and -50 ($p < 0.001$). The change in MPO for TPA model was -54 ($p < 0.001$), -65 ($p < 0.001$) and -36 ($p < 0.05$) respectively; for AA it was 0 (ns), -33 (ns) and -90 ($p < 0.001$). One hypothesis is that the AA administration to the ear overrides the need for PLA₂ mediated liberation of substrate for subsequent pro-inflammatory lipid mediator generation or AA mobilization by CoA-IT. In this case an inhibitor of an AA-metabolizing enzyme should be effective while an inhibitor of PLA₂ would be ineffective. As noted above, scalaradial and dexamethasone have little or no effect in the AA ear model at concentrations which were effective in the TPA ear model. This can be contrasted to the activity of the selective 5-LO inhibitor WY 50,295 which strongly inhibits inflammation in response to AA. The AA ear model therefore responds well to compounds that exhibit 5-LO inhibitory action and appears to be unaffected by putative PLA₂ inhibitors. This model therefore provides a unique tool with which the contribution of the 5-LO inhibition to the in vivo anti-inflammatory activity of various compounds can be separated from LMW-PLA₂ inhibition.

20

As used herein, various abbreviations and explanations are as follows: [³H], a molecule that contains tritium atoms, a radioactive isotope; A23187, a compound that allows free entry of calcium into a cell; AA, arachidonic acid; arachidonate, arachidonic acid contained within a phospholipid; free arachidonic acid, arachidonic acid that is not contained within a phospholipid; [²H₈]arachidonic acid, the form of arachidonic acid labeled with 8 deuterium atoms, a stable isotope; 1-alkyl, 1-*Q*-alkyl; 1-alkenyl, 1-*Q*-alk-1'-enyl; BSA, bovine serum albumin; CoA, coenzyme A; CoA-IT, CoA-independent transacylase; DTT, dithiothreitol; EGTA, [ethylenebis(oxyethylenenitrilo)]tetra acetic acid, a calcium chelator; GPC, sn-glycero-3-phosphocholine; EDTA, a metal ion chelator; GPE, sn-glycero-3-phosphoethanolamine; GC/MS, gas chromatography and mass spectrometry; 5HETE, 5(S)-hydroxyeicosa-6,8,11,14-tetraenoic acid; 15HETE, 15(S)-hydroxyeicosa-5,8,11,13-tetraenoic acid; HL-60, American Type Tissue Culture designated cell line similar to a monocyte; LTB₄, leukotriene B₄; LTC₄, leukotriene C₄; LTD₄, leukotriene D₄; lyso PAF, 1-alkyl-2-lyso-GPC, lyso platelet-activating factor; PLA₂, phospholipase A₂; PBS, phosphate buffered saline; PAF, platelet activating factor, 1-alkyl-2-acetyl-GPC; PL, phospholipid; PC, phosphatidylcholine; PE, phosphatidylethanolamine, PI, phosphatidylinositol; PMN, polymorphonuclear neutrophilic cell, neutrophil; PS

-31-


phosphatidylserine; R_f, the distance a compound travels as a fraction of the solvent front; TLC, thin layer chromatography; U937, American Type Tissue Culture designated cell line similar to a monocyte.

- 5 The above description fully discloses the invention including preferred
embodiments thereof. Modifications and improvements of the embodiments specifically
disclosed herein are within the scope of the following claims. Without further elaboration,
it is believed that one skilled in the art can, using the preceding description, utilize the
present invention to its fullest extent. Therefore, the Examples herein are to be construed
10 as merely illustrative and not a limitation of the scope of the present invention in any way.
The embodiments of the invention in which an exclusive property or privilege is claimed
are defined as follows.

-32-

What is claimed is:

1. A compound of the formula :



5

wherein

R_1 is $(CH_2)_nOH$ or $(CH_2)_nCO_2H$

n is 0 or an integer having a value of 1;

X is oxygen or sulfur;

1'0 W is $-NH$, $-N=CH-$, or $-S-$;

R_2 is hydrogen, halogen, optionally substituted C_{1-8} alkyl, or C_{1-8} alkoxy;

m is an integer having a value of 1 or 2;

R_3 is $S(O)_2R_7$;

R_4 is hydrogen;

1 5 R_5 is hydrogen, halogen, CF_3 , CH_3 , $(CH_2)_tC(O)_2R_8$, or $(CH_2)_tOH$;

t is 0 or an integer having a value of 1 or 2;

R_6 is hydrogen or halogen;

R_7 is optionally substituted aryl, optionally substituted aryl C_{1-2} alkyl, or an optionally substituted C_{1-8} alkyl;

2 0 R_8 is hydrogen or C_{1-4} alkyl;

or a pharmaceutically acceptable salt thereof.

2. The compound according to Claim 1 wherein R_1 is $(CH_2)_nCO_2H$.

2 5 3. The compound according to Claim 2 wherein R_7 is an optionally substituted aryl.

4. The compound according to Claim 2 wherein the aryl is a phenyl ring optionally substituted one to two times by halogen or trifluoromethyl.


3 0 5. The compound according to Claim 4 wherein the phenyl is di-substituted in the 3,5-positions by trifluoromethyl.

-33-

6. The compound according to Claim 6 wherein X is oxygen.
7. The compound according to Claim 1 wherein R₂ is hydrogen, halogen, or optionally substituted C₁₋₈ alkyl.
- 5 8. The compound according to Claim 1 wherein R₄ is hydrogen.
9. The compound according to Claim 1 wherein R₅ is hydrogen, halogen, or CF₃.
- 10 10. The compound according to Claim 1 which is
3-[2-[3,5-Bis(trifluoromethyl)phenylsulfonamido]-4-trifluoromethylphenoxy]picolinic acid, and preferably its lithium salt
3-[2-[3,5-Bis(trifluoromethyl)phenylsulfonamido]-4-trifluoromethylphenoxy]-2-hydroxypyridine;
- 15 3-[2-[3,5-Bistrifluoromethyl]phenylsulfonamido]-4-trifluoromethylphenoxy]pyrrole-2-carboxylic acid;
3-[2-[3,5-Bistrifluoromethyl]phenylsulfonamido]-4-trifluoromethylphenoxythiophene-2-carboxylic acid.
- 20 11. A pharmaceutical composition comprising a pharmaceutically acceptable diluent or carrier and a compound according to Claim 1.
12. A method for treating an inflammatory disease or disorder in a mammal in need thereof which method comprises administering to said mammal an effective amount of a
- 25 compound according to Claim 1.
13. The method according to Claim 12 wherein the inflammatory disease or disorder is allergic rhinitis, ischemia, reperfusion injury, arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, asthma, adult respiratory distress syndrome,
- 30 anaphylaxis, actinic keratosis, psoriasis, contact dermatitis, or pyresis.
14. The method according to Claim 13 wherein the inflammatory disease or disorder is mediated by lipid inflammatory mediators, arachidonic acid, its metabolites and/or platelet activating factor (PAF).
- 35 15. The method according to Claim 14 wherein the lipid inflammatory mediators are inhibited by the an inhibitor of the enzyme phospholipase A₂ (PLA₂).

-34-

16. A compound according to the formula:



5 wherein

X is oxygen or sulfur;

R₂ is hydrogen, halogen, optionally substituted C₁₋₈ alkyl, or C₁₋₈ alkoxy;

m is an integer having a value of 1 or 2;

R₃ is S(O)₂R₇;

10 R₄ is hydrogen;

R₅ is hydrogen, halogen, CF₃, CH₃, (CH₂)_tC(O)₂R₈, or (CH₂)_tOH;

t is 0 or an integer having a value of 1 or 2;

R₆ is hydrogen or halogen;

R₇ is optionally substituted aryl, optionally substituted arylC₁₋₂ alkyl, or an optionally substituted C₁₋₈ alkyl;

R₈ is hydrogen or C₁₋₄ alkyl;

or a pharmaceutically acceptable salt thereof.

17. The compound according to Claim 16 which is:

20 2-[2-[3,5-Bis(trifluoromethyl)phenylsulfonamido]-4-trifluoromethylphenoxy]pyridine, and pharmaceutically acceptable salts thereof.

18. A pharmaceutical composition comprising a pharmaceutically acceptable diluent or carrier and a compound according to Claim 16.

25

19. A method for treating an inflammatory disease or disorder in a mammal in need thereof which method comprises administering to said mammal an effective amount of a compound according to Claim 16.

30

20. The method according to Claim 19 wherein the inflammatory disease or disorder is allergic rhinitis, ischemia, reperfusion injury, arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, asthma, adult respiratory distress syndrome,

-35-

anaphylaxis, actinic keratosis, psoriasis, contact dermatitis, or pyresis.

21. The method according to Claim 20 wherein the inflammatory disease or disorder is mediated by lipid inflammatory mediators, arachidonic acid, its metabolites and/or platelet activating factor (PAF).
- 5

22. The method according to Claim 21 wherein the lipid inflammatory mediators are inhibited by the an inhibitor of the enzyme phospholipase A₂ (PLA₂).

10

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/07038

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61K 31/38, 31/40, 31/44

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/345, 350, 351, 423, 424, 445; 546/298, 300; 548/544, 546; 549/64, 65

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS ONLINE, APS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|-----------|--|-----------------------|
| A | US, A, 5,109,009 (NIELSEN ET AL) 28 April 1992, columns 1-2. | 1-14 |
| A, P | Medicinal Chemistry Research, Volume 4, issued 1994, Artico et al, "Pyrrolobenzothiazepines: a new class of non-nucleoside HIV-1 reverse transcriptase inhibitors" page 2, Scheme 1. | 1-10 |
| A | US, A, 4,954,518 (TAKANO ET AL) 04 September 1990, columns 52-53, Table 11. | 1-10 |
| A | US, A, 5,070,207 (SCHIEHSE ET AL) 03 December 1991, columns 1-3. | 12-15 |

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

| | | |
|--|-----|--|
| * Special categories of cited documents: | * T | later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention |
| * A | | document defining the general state of the art which is not considered to be of particular relevance |
| * E | | earlier document published on or after the international filing date |
| * L | | document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) |
| * O | | document referring to an oral disclosure, use, exhibition or other means |
| * P | | document published prior to the international filing date but later than the priority date claimed |
| | * X | document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone |
| | * Y | document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art |
| | * & | document member of the same patent family |

Date of the actual completion of the international search

04 AUGUST 1995

Date of mailing of the international search report

05 SEP 1995

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

Evelyn Huang

Telephone No. (703) 308-1235

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/07038

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-15

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US95/07038

A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

514/345, 350, 351, 423, 424, 445; 546/298, 300; 548/544, 546; 549/64, 65

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I, claim(s) 1-15, drawn to a compound with R1 and R2 substituted hetero ring.

Group II, claim(s) 16-22, drawn to a compound with R2 substituted pyridine.

The inventions listed as Groups I and II do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Group I compound structurally does not correspond to Group II compound because of the additional substitution of R1 and the different position of the heteroatom in the ring. Therefore, no linkage which forms a single general inventive concept can be established among the two inventions.